Herlev and Gentofte Hospital Department of Pediatrics



FACULTY OF HEALTH AND MEDICAL SCIENCES UNIVERSITY OF COPENHAGEN

Challenges in idiopathic/ genetic epilepsy syndromes



Maria J. Miranda, MD Ph.D., Department of Pediatrics, Herlev University hospital

NNPS, Copenhagen 2018

Indsæt h af objek

1. Højrek

vælg Git 2. Sæt ki tegnehja 3. Vælg (

REGION

og Navn omenuen Sidefod tår Navn r der står skrivelse

Anvend hkel slide Which challenges do we face when treating and following children with Childhood absence epilepsy (CAE) and Epilepsy with Centro-Temporal Spikes (ECTS)?





Childhood Absence Epilepsy (CAE)

Epilepsy with Centro-Temporal Spikes (ECTS)

Questions

- Treat or not to treat
- Which antiepileptic drug (AED)?
- Consequences?
- Risks?
- School?
- Future?





5.5 million inhabitants

~ 1,3% have epilepsy by age 15

 \sim 12.000 children have epilepsy in DK

15-25% = ECTS ~ 10% = CAE

New ILAE epilepsy classification: V. Etiology



Case S, 3,5 years old

- Girl S, born as twin A, GA 36+1, Apgar score 8/1 10/5
- Normal development
- Febrile seizures from 17 month old, x 7-8, last 2¹/₂ years old, uncomplicated
- Since the age of 3 y. 4 mo. many daily episodes lasting 5-10 seconds where she suddenly stares, stops activity, non-reacting, sometimes chewing loud

EEG



• EEG: Spike-wave 3 Hz paroxysms

Cont. case S

- EEG: 3 Hz generalised spike-wave paroxysms and several absences
- Starts Valproic acid (VPA), on 30 mg/ kg
- Starts ethosuximide (ETX) 5 weeks later, 25 mg/kg, VPA unchanged
- 2nd EEG ¹/₂ year later: normalised
- 2 year later (2016): medicine-free, absence-free and normal EEG
- Normal development, starts school

CAE history



g. 1.A. Simon-Auguste Tissot (1728–1797); B. Louis-Florentin Calmeil (1798–1895); C. Jean-Étienne Dominique Esquirol (1772–1840); D. Louis Jean François Delasiauve (1804–1893); John Russell Reynolds (1828–1896); F. Otto Binswanger (1852–1929); G. William Richard Gowers (1845–1915); H. Hans Berger (1873–1941).

- First described in 1705 by Poupart and Tissot in 1770
- 1924: hyperventilation and absences

1930: EEG

•

New ILAE epilepsy classification: V. Etiology



CAE EEG



• EEG: Spike-wave 3 Hz paroxysms

Challenges





Treatment

Developmental consequences



Treatment of CAE

VPA Valproic acid

ETX

Ethosuximide

LTG Lamotrigine

CAE treatment study



NIH Public Access

Author Manuscript

N Engl J Med. Author manuscript; available in PMC 2010 September 4.

Published in final edited form as:

NEngl J Med. 2010 March 4; 362(9): 790-799. doi:10.1056/NEJMoa0902014.

Ethosuximide, Valproic Acid, and Lamotrigine in Childhood

Absence Epilepsy

Tracy A. Glauser, M.D., Avital Cnaan, Ph.D., Shlomo Shinnar, M.D., Ph.D., Deborah G. Hirtz, M.D., Dennis Dlugos, M.D., David Masur, Ph.D., Peggy O. Clark, M.S.N., Edmund V. Capparelli, Pharm.D., and Peter C. Adamson, M.D. [on behalf of for the Childhood Absence Epilepsy Study Group]^{*}

A double-blind RCT comparing efficacy, tolerability and neuropsychological effects of ETX, VPA and LTG in children with CAE.

CAE study

- ETX and VPA were similar in efficacy
- LTG less efficacy
- ETX better cognitive profile
- ETX less relapse
- Patients with no response to ETX: Higher risk of GTCs and progression to JME
- ETX: disease-modifying effect?

Treatment protocol

- ETX:
 - Start 10 mg/ kg, increase every 5th day to 20-40 mg/kg
 - Side effects: gastrointestinal, tiredness



Ethosuximide: Zarondan® syrup or Petnidan® capsules (in DK requires special application to Danish Medicines Agency)

Developmental consequences CAE

- 36% have attention deficits before treatment start (x 4 background population)
- IQ: normal
- Attention deficits similar in seizure-free and nonseizure free
- Important to pay attention to school achievements and children's well-being

CAE-prognosis

12% had GTCS throughout 7 years

CAE-prognosis

Bad prognosis: Lack of response to 1st choice treatment Good prognosis: Response to ETX ECTS- Epilepsy with Centro-temporal spikes or Rolandic Epilepsy

- Self-limited idiopathic/ genetic focal epilepsy syndrome
- 25% of epilepsies in children under 16 years
- 2/3 of self-limited focal epilepsy syndromes
- Peak of onset 5-8 years (2-14 years)

New ILAE epilepsy classification: V. Etiology

Classification of the Epilepsies

Seizure types* Etiology Generalized Focal Unknown Structural rbidities denetic Figure 1. Epilepsy types Infectious Framework for classification of the epilepsies. *Denotes onset of seizure, Combined 0 Unknown Focal Generalized Generalized Epilepsia © ILAE Metabolic & Focal 0 Immune **ECTS** Unknown **Epilepsy Syndromes** Syndrome: self-limited idiopathic/ genetic focal 22 epilepsy syndrome

Seizures in ECTS



- Only 20% have frequent seizures
- Brief seizures, 1-2 min.
- 70% in sleep (may occur during wakefulness, far lees common)

ECTS- EEG awake

	00:00:00	00:05:00	[≜] 00:10:00	00:15:00	00:20:00	00:25:00	00:30:00	00:35:00	00:40:0
AOGI ~~					m		m		
Fp1-AVLF	monument	month	mmmmm	monormany	mannan	a mining of	Munhammun	mond	nonmin
	mmmmmm	mmmmm	mont	manny	have a manufactured	have have been a	Montenant	mon and	non
F3-AVLR	min month man	mound	mmmmm	mmmmm	and many	monter	Minimum	moning	mm
F4-AVLR	mmmmmmm	Mummun	mound	mamman	an many many	manyman	Mymmum	mannin	minn
F9-AVLR	mmmmmm	mmm	mmmm	mound	1 hoursonly	Marinandan	man man	manim	mmm
	mmonthing	mmmm	MMMmmm	hummin	mant	Murmund M	mannon	man	mon
F7-AVLR	mannaman	mmm	minum	- Mummun	manna	minimum	mannon	monorm	mmum
F8-AVLR	mmmmmm	mount	month	man man	monthly	month	mb Man Man	mmmm	mmm
T9-AVLR	mannan	moun	mannon	mmunh	mum	man	mmmm	mann	mm
	man when when the second	mmm	Mannen	month	mont	mmmm	MMMmmm	mound	mm
T7-AVLR	monthemation	Munum	mm	mymmy	many	mann	mound	month	mmm
18-AVLR	man	Mundan	vin with the	man man	montorm	month	Munh	wwwww	mmm
P9-AVLR	www.www.wwwww	Marian	www.www.	more when when when when when when when whe	manning	mummum	www.monterior	www.www	mon
	month many many	www.w	Munum	mannen	manne	mont	mont	m	man
P7-AVLR	www.www.www.www.www.www.www.www.www.ww	www.	MMMMM	mont	mannen	mann	Manum	many	man man
P8-AVLR	m mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm	wwwww	MMMmmmm	Marthan	Manymouth	1 Pm Manument	Mr. Marine	mm	mum
C3-AVLR	manna	mmm	v. www.	-Min Marine	mont	Mumm	www.www.	minn	mm
C4-AVLR	www.www.www.www.	mmm	MMMMM	- A Martin Martin	mound	an many many	- Million Marine Mari	mann	Munu
P3-AVLR	www.www.	www.ww	MMMM	mmmmmm	Mummum	Muhhmm	man	wwwwww	mound
P4-AVLR	man man	minim	mm	www.	munit	programment and	www.www.	mm	Murum
01-AVLR	Martine Male	handren	www.www.	mmunum	mmm	Multiman	MMMMM	wwwwwww	wwwww
02-AVLR	-marken and my my my my	marra Ma	mun many	www. www. www.	No Marine Mar	Murmon	Manna	manner	mount
Fz-AVLR	mand	1 mm	Monterent	m have her all	mun	ma Marchand Anna	M. M	www.www.	mun
Cz-AVLR	Mannan	www.	mannen	Murana	www.www.	man man	My Marken Marken Mark	when when	Mun
Pz-AVLR	M.M.M.M.M.	mmmm	www.man	- Mannen - Marine - M	www.ww	walnum	MM	MANNA	WWWwww
EKG	m m	-h-h-h		mont	-b-b-b	n-but-but	-martin-	m	-
SpO2									
Photic									
13:0 Deedu	12:00 LwR ComAy, 30 mm/sec, 100 µV/cm, 70,0 H:	z, 0,500 Hz, Notch Off						a Baadar 13:03:00:00	13/03/00
Reauy							Gið Rúði	ic Reduct 15:02:00:00	13.02.00 00:

ECTS-EEG sleep



Prognosis ECTS



- For seizure remission good
- Self-limited in most children by 15-16 years
- And usually within
 2-4 years of onset 26



ECTS-comorbidity

Neuro-cognitive and behavioural:

increasing evidence of significant difficulties



ECTS- comorbidity



- 12-30% difficulties in:
 - Language
 - Memory
 - Behaviour
 - Attention
 - Anxiety
 - Depression
 - Cognition...

ECTS- evolution

• ECTS

- CSWS/ ESES (electric status epilepticus in slow sleep)
- Landau-Kleffners syndrome (acquired aphasia)
- ECTS with frequent refractory seizures



ECTS- treatment challenges

- Treat or not to treat
 - individual decision
 - seizure frequency
 - parents/ child
 - Cost/ benefit
- Which AED?
 - No clear scientific evidence
 - Levetiracetam
 - Others: Valproic acid, Sulthiam

Questions and challenges regarding ECTS

• AED reduces seizures: YES



- EEG SW activity in sleep correlates with comorbidities??
- AED ameliorates EEG SW activity in sleep??
- AED reduces comorbidity??
- AED may prevent (or worsen) development to atypical evolution of ECTS? 31

Treatment with AED- challenges (cont.)

- Will AED reduce SW-frequency under sleep?
 - Some evidence
- Reducing SW in sleep by treating with AED, will we ameliorate cognitive and behavioural issues?
 - No clear scientific evidence



Take home messages

TREATMENT: CAE: 1. choice ETX ECTS: Individual (start LEV?)

DEVELOPMENTAL CHALLENGES: CAE: YES

ECTS: YES



Take home messages

• Treat right from the beginning

- Be aware of children's school difficulties, behaviour and psychiatric symptoms
- Be aware of changes

